Given that cancer is one of the leading causes of death worldwide, oncology has urgent unmet patient needs. It is also an area that has seen the development of a steady string of new drugs in line with scientific advancement. To meet the unmet medical needs of both patients and the healthcare professionals who treat them, Astellas works to lead the way in product offerings and development.

Our current suite of four oncology products – XTANDI®, Eligard® and Gonax® for prostate cancer and Tarceva® for the treatment of non-small cell lung and pancreatic cancers – are already helping to improve the lives of people. We remain committed to expanding how these existing therapies can make a difference for new patients as well as to expanding our current portfolio with additional novel therapies. 

In fact, we have Phase 1, 2 and 3 trials underway that are examining the development of innovative therapies for hard-to-treat cancers with limited therapeutic options, which is where we see the most promise and the greatest opportunity to help patients. Working with our colleagues and partners across the globe, we believe we are on the cusp of being able to introduce new therapies that will provide meaningful, groundbreaking cancer treatment for millions of people worldwide.